HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.

AuthorsNeil M Bressler, Susan B Bressler, Laurie A Haynes, Yong Hao, Peter K Kaiser, Joan W Miller, Joel Naor, Michael J Potter, Constantin J Pournaras, Al Reaves, Philip J Rosenfeld, Ursula Schmidt-Erfurth, Jason S Slakter, Andrew Strong, Stéphane Vannier
JournalArchives of ophthalmology (Chicago, Ill. : 1960) (Arch Ophthalmol) Vol. 123 Issue 9 Pg. 1283-5 (Sep 2005) ISSN: 0003-9950 [Print] United States
PMID16157822 (Publication Type: Clinical Trial, Letter, Randomized Controlled Trial, Comment)
Chemical References
  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin
Topics
  • Aged
  • Choroidal Neovascularization (drug therapy, etiology)
  • Female
  • Follow-Up Studies
  • Humans
  • Macular Degeneration (complications, drug therapy)
  • Male
  • Photochemotherapy
  • Photosensitizing Agents (therapeutic use)
  • Porphyrins (therapeutic use)
  • Time Factors
  • Verteporfin
  • Visual Acuity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: